# Jacob Kimmel

> Jacob C. Kimmel is a computational biologist and NewLimit co-founder and CEO. His path runs from time-lapse cell imaging at UCSF through data science and laboratory leadership at Calico to building a company that combines biological experiments with machine learning. He also writes public progress reports and maintains open-source research tools.

- **Role:** Co-founder and CEO at NewLimit
- **Organizations:** NewLimit, Calico Life Sciences, University of California, San Francisco, IBM Research
- **Education:** Ph.D., Biochemistry and Biophysics (stem cell biology research), University of California, San Francisco
- **Known for:** Co-authored peer-reviewed research on cell state, single-cell classification, and reprogramming., Co-developed scNym, open-source software for single-cell classification., His 2020 scNym work received an ICML Computational Biology workshop top-paper award.

## Career timeline

- **2015-2018** — Completed doctoral research at UCSF, developing methods to infer cell state from time-lapse imaging.
- **2017** — Deep learning research intern in IBM Research’s Cell Engineering Group.
- **2018-2020** — Data scientist in Calico Life Sciences’ Computing group.
- **2020-2021** — Computational Fellow at Calico.
- **2021-2022** — Principal Investigator at Calico, leading a laboratory combining computational and experimental methods.
- **2021-2022** — Co-founded NewLimit; company materials variously date founding to 2021 and 2022.
- **2022-2026** — Served as NewLimit head of research and president before becoming CEO.
- **2026-06** — Announced NewLimit’s $435 million Series C as CEO.
- **2026-07** — Published a company progress report on model generalization and manufacturing scale.

## Achievements

- Co-authored peer-reviewed research on cell state, single-cell classification, and reprogramming.
- Co-developed scNym, open-source software for single-cell classification.
- His 2020 scNym work received an ICML Computational Biology workshop top-paper award.
- Received an NSF Graduate Research Fellowship, UCSF Discovery Fellowship, and PhRMA Informatics Fellowship.
- Led NewLimit as it announced a $435 million Series C in June 2026.

## Latest updates

- **2026-07** — Published a May-June progress report describing model generalization across cell types, new team members, and manufacturing scale-up.
- **2026-06** — Announced NewLimit’s $435 million Series C and a target of first human trials in 2027.
- **2026-06** — Hosted and published NewLimit’s annual progress presentation.

## Links

- Website: https://jck.bio/
- LinkedIn: https://www.linkedin.com/in/jacob-kimmel
- Twitter/X: https://x.com/jacobkimmel
- GitHub: https://github.com/jacobkimmel

---

Profile page: https://yespress.io/jacob-kimmel
Published by YesPress — https://yespress.io
Last updated: 2026-09-29